[Amended] Material event report (equity acquisition)

A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-10-16) →

What happened

Decision to Acquire Equity and Other Securities of Another Company 6.1

Samsung Biologics Co., Ltd.

Amendment Report August 28, 2026

1. Disclosure document being amended: Material Event Report (Acquisition of Equity and Other Securities of Another Company) 2. Original filing date of the disclosure document being amended: 2026-07-20 3. Amended items:

Item 7 (Payment of transaction price): Reason for amendment - Change of funding method Before: 1) Payment method: Cash payment; 2) Payment timing: Within 10 business days after the close of the tender offer and business-combination approval; 3) Funding method: Own funds and borrowings After: 1) Payment method: Cash payment; 2) Payment timing: Within 10 business days after the close of the tender offer and business-combination approval; 3) Funding method: Funds raised through a rights offering or similar means

Item 15 (Other material matters relevant to investment decisions): Before: A portion of the tender-offer price is planned to be funded by borrowings; other funding methods may be considered later, and if specific borrowing terms or a funding plan are finalized, an amendment disclosure will be made. After: The acquisition funds are planned to be raised through a rights offering or similar means; the Company's own funds will be used to cover any variance that arises during the process.

Material Event Report / Exchange Reporting Obligation To the Financial Services Commission / Korea Exchange 2026-07-20

Company name: Samsung Biologics Co., Ltd. Representative Director: Lim Jon-jong-bo (as stated in the filing) Head office address: 300 Songdo Bio-daero, Yeonsu-gu, Incheon (Phone) 032-455-3114 (Website) http://www.samsungbiologics.com Preparer: (Title) Head of Management Support Center (Name) Yoo Seung-ho (Phone) 032-455-3114

Decision to Acquire Equity and Other Securities of Another Company

1. Issuing company: Company name PolyPeptide Group AG; Nationality Switzerland; Representative Juan Jose Gonzalez; Capital stock (KRW) 612,742,956; Relationship with the Company - Not applicable; Total issued shares 33,125,001; Main business Peptide CDMO; Whether new shares were acquired via third-party placement within the past 6 months: Not applicable

2. Acquisition details: Number of shares acquired 33,016,411; Acquisition amount (KRW)(A) 2,706,163,546,103; Total assets (KRW)(B) 11,060,741,976,837; (A/B) 24.47%; Equity capital (KRW)(C) 7,451,110,647,985; (A/C) 36.32%

3. Shares owned and ownership ratio after acquisition: Shares owned 33,016,411; Ownership ratio 100%

4. Purpose of acquisition: To strengthen business competitiveness through the acquisition of a peptide CDMO company.

5. Expected transfer date: 2026-11-30

6. Transaction counterparty: Company name (persons) Draupnir Holding B.V. and other tendering shareholders; Capital stock (KRW) 685,078,200,000; Main business Holding-company and management-consulting business; Head office address Siriusdreef 29, 2132WT Hoofddorp, Netherlands; Relationship with the Company - Not applicable

7. Payment of transaction price: 1) Payment method: Cash payment 2) Payment timing: Within 10 business days after the close of the subscription period and business-combination approval 3) Funding method: Funds raised through a rights offering or similar means

8. External valuation Whether an external valuation was conducted: Yes - Basis and reason: 1) Basis: For use as an attachment to the material event report filed with the Financial Services Commission pursuant to Article 161 of the Financial Investment Services and Capital Markets Act and Article 171 of its Enforcement Decree. 2) Reason: To provide reference material for assessing the appropriateness of the acquisition price in acquiring shares of the issuing company, and for use as an attachment to the material event report filed pursuant to the Financial Investment Services and Capital Markets Act. - Name of external valuation agency: Anjin Accounting Corporation - External valuation period: 2026-07-14 to 2026-07-17 - External valuation opinion: Based on the valuer's analysis, the per-share value of the shares to be acquired was calculated to range from a minimum of CHF 31.43 to a maximum of CHF 63.22. Accordingly, your Company's acquisition price of CHF 44.31 per share was not found to have any basis for being judged inappropriate from a materiality perspective, considering precedents of control-premium transactions in listed companies.

9. Board resolution date (decision date): 2026-07-17 - Independent (outside) director attendance: Present 4; Absent 0 - Attendance of the statutory auditor (or audit committee member who is not an independent/outside director): Not applicable

10. Whether this constitutes a backdoor listing: No - Plans for third-party placement capital increase, etc. within the next 6 months: No

11. Whether the issuing company (the other company) meets the backdoor-listing requirements: Not applicable

12. Whether subject to reporting to the Fair Trade Commission: Not applicable

13. Whether a put option or similar agreement was entered into: No; Contract details: Not applicable * "Independent director" applies to listed companies; "outside director" applies to unlisted companies.

1) The "capital stock" of the issuing company under Item 1 above is CHF 331,250.01 converted at the base exchange rate of the first trading day, 2026-07-16 (CHF/KRW 1,849.79), and the "total issued shares" figure is as of the filing date of this report. 2) The "number of shares acquired" under Item 2 above ("Acquisition details") is the maximum planned acquisition quantity, assuming acquisition of the entire 33,125,001 total issued shares less 108,590 treasury shares; the actual number of shares acquired and the resulting ownership and ratio after acquisition may differ depending on the results of shareholders tendering into this tender offer. The "acquisition amount (A)" is based on CHF 1,462,957,171.41 (the tender-offer price of CHF 44.31 per share multiplied by the above 33,016,411 shares), converted at the base exchange rate of 2026-07-16 (CHF/KRW 1,849.79); the actual acquisition amount may differ depending on the tender results and the exchange rate applicable at the time the acquisition is completed. "Total assets (B)" and "equity capital (C)" are based on the Company's consolidated financial statements prepared in accordance with Korean IFRS as of 2025-12-31. 3) The "ownership ratio" under Item 3 above is the "shares owned" divided by the total issued shares less treasury shares. 4) The "expected transfer date" under Item 5 above is the expected settlement date for shares acquired through this tender offer. The specific schedule may change depending on the progress of the tender-offer procedure, whether the tender-offer conditions are satisfied or waived, and the approval schedule of relevant authorities, including business-combination and foreign-investment approvals. 5) The "capital stock" of the transaction counterparty under Item 6 above is EUR 401,250,000 converted at the base exchange rate of 2026-07-16 (EUR/KRW 1,707.36). 6) For other details, please refer to the attached external valuation agency's opinion letter.

14. Future plans for corporate restructuring: As of the filing date of this report, no specific plans for future restructuring have been finalized.

15. Other material matters relevant to investment decisions: - The Company plans to acquire the issuing company's registered shares, which are listed on the Swiss stock exchange, via tender offer, either directly or through a Swiss subsidiary to be established before commencement of the tender offer. If the tender offeror is ultimately determined through establishment of a subsidiary, etc., the Company will disclose this. - Draupnir Holding B.V., the issuing company's largest shareholder, has undertaken to tender all 18,375,000 shares (55.65% = 18,375,000/33,016,411) of the issuing company it holds as of the filing date of this report into this tender offer. - This tender offer is conditioned on the number of shares validly and irrevocably tendered by the end of the tender-offer period (including the shares the largest shareholder has undertaken to tender) being at least approximately 66.7% (2/3) of the issuing company's fully diluted capital stock (the "minimum tender condition"); if the minimum tender condition is not met, none of the tendered shares will be purchased. - If the minimum tender condition or other tender-offer conditions are not satisfied or waived, this share acquisition may not take place. - The acquisition funds are planned to be raised through a rights offering or similar means; the Company's own funds will be used to cover any variance that arises during the process. - The above details may change depending on the progress of this tender offer and related approval procedures, and an amendment disclosure will be made in accordance with relevant laws when material matters are finalized. * Related disclosures: None

[Summary Financial Status of the Issuing Company] (unit: KRW million) Category: Total assets; Total liabilities; Total equity; Capital stock; Revenue; Net income (loss); Audit opinion; External auditor Current year: 1,410,209; 828,686; 581,523; 613; 669,198; -36,143; Unqualified; BDO Ltd Prior year: 1,291,748; 681,803; 609,944; 613; 578,402; -33,403; Unqualified; BDO Ltd Year before that: 1,176,521; 525,633; 650,888; 613; 554,641; -87,827; Unqualified; BDO Ltd 1) The "current year" above is based on the consolidated financial statements as of the end of 2025; "prior year" as of the end of 2024; "year before that" as of the end of 2023. 2) The [Summary Financial Status of the Issuing Company] above applies the base exchange rates of the first trading day, 2026-07-16 (EUR/KRW 1,707.36, CHF/KRW 1,849.79).